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Vitamin D and diabetes 
mellitus: an update – 2013
Vitamin D e diabetes melito: uma atualização – 2013
Luiz Henrique Maciel Griz1, Francisco Bandeira1, Mônica Andrade 
Lima Gabbay2, Sergio Atala Dib2, Eduardo Freese de Carvalho3 
ABSTRACT
Vitamin D deficiency and diabetes mellitus are two common conditions and they are widely prevalent 
across all ages, races, geographical regions, and socioeconomic conditions. Epidemiologic studies 
have shown association of vitamin D deficiency and increased risk of chronic diseases, such as can-
cer, cardiovascular disease, type 2 diabetes, and autoimmune diseases, such as multiple sclerosis 
and type 1 diabetes mellitus. The identification of 1,25(OH)2D receptors and 1-α-hydroxilase expres-
sion in pancreatic beta cells, in cells of the immune system, and in various others tissues, besides 
the bone system support the role of vitamin D in the pathogenesis of type 2 diabetes. Observational 
studies have revealed an association between 25(OH) D deficiency and the prevalence of type 1 dia-
betes in children and adolescents. This review will focus on the concept of vitamin D deficiency, its 
prevalence, and its role in the pathogenesis and risk of diabetes mellitus and cardiovascular diseases. 
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RESUMO
A deficiência de vitamina D e o diabetes melito são enfermidades comuns na população e são alta-
mente prevalentes em todas as raças, idades, regiões geográficas e situação socioeconômica. Es-
tudos epidemiológicos mostram uma associação entre hipovitaminose D com o aumento do risco 
de doenças crônicas, tais como câncer, doença cardiovascular, diabetes melito do tipo 2 e doenças 
autoimunes como a esclerose múltipla e o diabetes mellitus do tipo 1. A identificação de receptores 
da 1,25(OH)2 D e da expressão da 1 α-hidroxilase nas células betapancreáticas, em células do sistema 
imunológico e em uma variedade de células do organismo além do tecido ósseo, suporta o papel da 
vitamina D na patogênese do diabetes tipo 2 e do tipo 1. Esta revisão apresenta e discute o conceito 
de deficiência de vitamina D, sua prevalência e seu papel na patogênese e no risco de desenvolvi-
mento do diabetes melito e doenças cardiovasculares. Arq Bras Endocrinol Metab. 2014;58(1):1-8
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INTRODUCTION
V itamin D deficiency and diabetes mellitus are two common conditions in the elderly population. 
Vitamin D deficiency is currently a topic of intense in-
terest, and is widely prevalent across all ages, races, ge-
ographical regions, and socioeconomic strata. Subopti-
mal vitamin D status contributes to many conditions, 
including osteomalacia, osteoporosis, falls, and fractu-
res (1,2). In addition, epidemiologic observations have 
associated low vitamin D status with an increased risk of 
non-musculoskeletal diseases, such as cancer (3), mul-
tiple sclerosis (4), type 1 diabetes mellitus (5), type 2 
diabetes mellitus (6) and cardiovascular disease (7).
Vitamin D (calciferol) is a generic name for a 
group of fat steroids of which the two major forms 
are vitamin D2 (ergocalciferol) and vitamin D3 
(colecalciferol). Both forms of vitamin D undergo 
identical metabolism. Vitamin D is obtained from skin 
irradiation and limited dietary sources. Vitamin D from 
the skin and diet is metabolized in the liver to 25(OH)
D, which has a long life and is the major circulating 
metabolite and marker of vitamin D status (8). In the 
kidney, 25-hydroxyvitamin D is metabolized by the 
enzyme 25-hydroxyvitamin D-1(alpha)-hydroxylase 
(CYP27B1) to its active form, 1,25(OH)2D, which 
exerts its effects by means of steroid hormone nuclear 
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receptors. The characteristics of 1,25(OH)2D are those 
of a hormone, and consequently vitamin D is a pro-
hormone, rather than a true vitamin. 
Vitamin D is not only essential for maintaining bone 
health, but it also plays a role in several other biochemical 
mechanisms within the human body. The mechanism 
of action of the active form of vitamin D is similar to 
that of other steroid hormones and is mediated by its 
binding to vitamin D receptor (VDR). VDRs are found 
in most tissues, not just in those that participate in the 
classic actions of vitamin D such as bones, intestines 
and kidneys, and the enzyme responsible for converting 
25 (OH)D to 1,25(OH)2D is also expressed in a variety 
of extrarrenal sites, such as endothelial cells, beta cells, 
and immune cells (9).
The number of subjects with type 2 diabetes mellitus 
is rising, due to effect of age, growth of the population, 
sedentariness and, mainly, obesity. Although changes in 
lifestyle, particularly weight loss and physical activity, 
delay the progression of diabetes, weight loss is diffi-
cult to be achieved and maintaind. The identification 
of easily modifiable risk factors is therefore urgently 
needed for primary prevention of diabetes. Certain nu-
tritional factors, such as vitamin D are also believed to 
play a role, and it has been suggested that endemic low 
vitamin D status contributes to the increased preva-
lence of diabetes mellitus. There is increasing evidence 
that vitamin D metabolism affects the risk of diabetes. 
Studies in  humans have shown that vitamin D supple-
mentation in infancy reduces the risk of type 1 diabetes 
mellitus during early adulthood (10). Published studies 
in animals identified a pancreatic receptor to the ac-
tive metabolite of vitamin D. As vitamin D modulates 
insulin receptor gene expression and insulin secretion, 
it is an interesting environmental candidate for type 2 
diabetes mellitus (11). 
This review will focus on the concept of vitamin 
D, its prevalence, and its role in the pathogenesis of 
diabetes mellitus, its risks and complications.
CONCEpT AND pREvAlENCE Of vITAMIN D 
INSUffICIENCy AND DEfICIENCy 
The concept of normal 25(OH)D concentration is 
a challenge. It has been suggested that vitamin D 
deficiency be defined as a 25(OH)D below 20 ng/
mL, insufficiency as a 25 (OH)D of 21 – 29 ng/mL, 
and sufficiency as a 25 (OH)D of 30 – 100 ng/mL (to 
convert to nanomoles per liter, multiply by 2.496) (12). 
A meta-analysis of high-quality primary prevention 
randomized control trials (RCT) of vitamin D and 
fracture risk consistently found that antifracture efficacy 
started at 25(OH)D levels of at least 30 ng/mL (13).
The guideline, written by the Endocrine Society 
Task Force, reports that 25(OH)D levels of 30 ng/
mL or higher compared with 20 ng/mL provide 
increase benefits (14). In contrast, the Institute of 
Medicine (IOM) report, based on evidence from 
observational studies and recent randomized trials, 
suggests that a serum level of 20 ng/mL of 25(OH)
D would protect 97.5% of the population against 
adverse skeletal outcomes (15). Hypovitaminosis D has 
become endemic owing to the insufficient ingestion 
of vitamin D in combination with the use of sun 
protection clothing and sunblocks. The prevalence 
of vitamin D deficiency has been reported with great 
frequency even in sunny regions of the world. Studies 
on the prevalence of hypovitaminosis D in Saudi 
Arabia, Australia, Turkey, the Arab Emirates and India 
have shown that 30%-50% of children and adults had 
25(OH)D levels below 20 ng/mL. In Recife (latitude 
10ºS), Pernambuco,Brazil, the prevalence of vitamin 
D deficiency in postmenopausal women was 8% for 
25(OH)D values below 15 ng/mL and 43% for those 
below 25 ng/mL (16).
An observational study carried out in Italy in 
postmenopausal women revealed that vitamin D levels 
in postmenopausal women were lower in those with 
type 2 diabetes mellitus than in those in the control 
group (39% vs. 25%) (17). A Japanese study evaluating 
581 diabetic patients and 51 nondiabetic ones showed 
a prevalence of hypovitaminosis D (< 20 ng/mL) of 
75% with no differences between the type 2 diabetic 
patients and the control group (18). A study carried 
out in United Kingdom evaluated the prevalence of 
hypovitaminosis D in type 2 diabetic patients in an Asian 
community and its impact on the control of glycemia 
(19). The results revealed that the prevalence of vitamin 
D (< 20 ng/mL) was > 80%, being more common in 
the diabetics than in the control group (83% vs. 70%; 
p = 0.07), and that the glycated hemoglobin levels were 
higher in the women with vitamin D deficiency.
vitamin D and insulin resistance
The identification of 1,25(OH)2D receptors and 
the 1 α hydroxilase expression in pancreatic beta 
cells support the possibility of vitamin D role in the 
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pathogenesis of type 2 diabetes mellitus (20). In 
animals it has been demonstrated that the secretion of 
pancreatic insulin is inhibited by vitamin D deficiency 
(21) and that in humans vitamin D deficiency is related 
to glucose intolerance and type 2 diabetes mellitus 
(22). Hypovitaminosis D leads to a deficiency in the 
secretion of insulin and induces glucose intolerance 
(23), while its replacement with vitamin D reestablishes 
these abnormalities (24). 
Vitamin D affects the function of beta cells in various 
ways. The active form of vitamin D exerts its effects 
by activating the nuclear vitamin D receptor (VDR). 
The binding of 1,25(OH)2D to the VDR leads to the 
transcription of genes regulated by 1,25(OH)2D. The 
effect of vitamin D on insulin synthesis and secretion is 
evidenced by the presence of the vitamin D response 
element (VDRE) in the human insulin gene promoter 
and transcriptional activation of the human insulin 
gene caused by 1,25(OH)2D (25).
 An indirect effect 
of vitamin D on beta cells may be mediated by its 
regulation in the extracellular concentration of calcium 
and the influx of calcium through the beta cells (26). 
Vitamin D may also affect insulin resistance through 
the renin-angiotensin-aldosterone system. It is believed 
that angiotensin II contributes to increased insulin 
resistance by inhibiting the action of insulin in the 
vascular tissue and skeletal muscle, leading to a decrease 
in glucose uptake (27). Data support the vitamin 
D-VDR complex as a potential regulator of renin 
activity in humans and polymorphisms in the VDR 
gene may be associated with the pathogenesis of type 2 
diabetes mellitus by influencing insulin resistance (28). 
However, whether vitamin D may influence insulin 
secretion and action is controversy. Although some 
studies found no association between serum 25(OH)
D levels and parameters of insulin action (29), others 
have shown positive associations. In the Canadian 
Prospective Metabolism and Islet cell Evaluation 
(PROMISE) study cohort (30), three univariate 
analyses indicated a significant positive association 
between serum 25(OH)D and the insulin sensitivity 
index for the oral glucose tolerance test (IS-OGTT): r 
= 0.30, p < 0.001. A significant negative association was 
found between serum 25(OH)D and the homeostasis 
model assessment (HOMA-IR): r = -0.29, p < 0.001, 
as well as significant positive associations between 
serum 25(OH)D levels and the insulinogenic index/
HOMA ratio: r = 0.14, p = 0.002. In the multivariate 
regression analyses, serum 25(OH)D was a significant 
independent predictor of insulin sensitivity and beta 
cell function across all models (31).
In HIV positive patients there is prolonged exposure 
to the HIV virus and anti-retroviral therapy (ART), and 
both have been associated with metabolic abnormalities 
and insulin resistance. Vitamin D deficiency has been 
reported to be higher in various age groups of HIV-
infected individuals, ranging from 60% of adolescents 
and young adults with serum 25(OH)D levels of less 
than 10 ng/mL in the Netherlands (32) (40° N) to 
more than 80% of adults, with a mean age of 41 years, 
showing serum 25(OH)D levels of less than 18 ng/
mL in Italy (30° N). In a group of premenopausal HIV 
women with a mean age of 40 years living in the city 
of Recife (10° S), 60% of them with lipodystrophy, 80% 
with dyslipidemia and 38% with metabolic syndrome, 
we found a 41% prevalence of vitamin D deficiency 
using a cut point of 30 ng/mL for serum 25(OH)D. 
After full adjustments, total serum cholesterol levels 
and the duration of ART were independently associated 
with vitamin D deficiency (33).
vitamin D and type 2 diabetes mellitus 
Vitamin D deficiency appears to predispose individuals 
to becoming type 2 diabetics, and there is evidence 
from observational studies that suggests an association 
between low levels of vitamin D and a risk of type 2 
diabetes mellitus. 
A decrease in the concentration of vitamin D was 
reported in a population of Asians from Bangladesh 
resident in London at risk for type 2 diabetes mellitus 
compared with individuals with no such risk and who 
also presented a higher prevalence of type 2 diabetes 
mellitus than a British Caucasian population (34). 
An English cohort (6) comprising a total of 524 
randomly selected nondiabetic men and women, aged 
40-69 years at baseline, with measurements for serum 
25(OH)D and IGF-1 in the population-based Ely Study, 
had their glycemic status (oral glucose tolerance), lipids, 
insulin, anthropometry, and blood pressure measured 
and metabolic syndrome risk (metabolic syndrome z 
score) derived at baseline and at 10 years of follow-
up. This prospective study reports inverse associations 
between baseline serum 25(OH)D and future 
glycemia and insulin resistance. These associations are 
independent of risk factors and potential confounders. 
These findings confirm results from a Finnish cohort 
study showing a significant inverse association between 
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serum 25(OH)D and risk of type 2 diabetes in a simple 
model. However, the association was attenuated in the 
multivariate analysis, adjusting for potential risk factors 
for type 2 diabetes. 
An analysis from the Nurse Health Study 
demonstrated that women with a mean ingestion of 
vitamin D greater than 800 IU per day had a 33% lower 
risk of type 2 diabetes mellitus than those whose daily 
ingestion was less than 200 IU (35). 
To determine the association between serum 25(OH)
D and diabetes risk and whether it varies according to 
ethnicity, an analysis of data from the Third national 
and Nutrition Examination Survey (1988-1994) was 
carried out. In this cross-sectional survey of a nationally 
representative sample of the U.S population, 25(OH)D 
was available from 6,228 people (2,766 non-Hispanic 
whites, 1,736 non-Hispanic blacks, and 1,726 Mexican 
Americans), aged ≥ 20 years with fasting and/or 2-h 
plasma glucose and serum insulin measurements. The 
results showed an inverse association between vitamin 
D status and diabetes, possibly involving resistance, in 
non-Hispanic whites and Mexican Americans, but not 
in non-Hispanic blacks (36). 
All this data suggests that hypovitaminosis D may 
be a major risk factor in glucose intolerance in some 
individuals, but not in all populations. One explanation 
for the lack of association could be the existence of 
a variable effect in the threshold between different 
ethnic groups. It is possible that a particular population 
may have a diminished sensibility to vitamin D or to 
the effects of the parathyroid hormone (PTH). A 
cross-sectional study performed on obese female 
adolescent Afro-Americans suggested that 25(OH)D 
concentrations < 15 ng/mL represent the threshold 
from which vitamin D deficiency produces a negative 
effect on insulin sensibility (37), and adolescents in 
NHANES III with serum 25(OH)D levels of less than 
15 ng/mL were more likely to have elevated blood 
glucose levels than those with the highest 25(OH)D 
values (> 26 ng/mL) (OR, 2.5; 95% CI, 1.0-6.4) (38).
Unlike observational studies, experimental studies 
lack evidence to support the hypothesis that vitamin 
D supplementation reduces the risk of diabetes or 
glucose intolerance. In a meta-analysis (39) published 
in 2007, none of the six studies reviewed was able to 
demonstrate a significant change in glucose intolerance. 
However, three of the studies were of short duration 
(≤ 3 months), and two of these employed the active form 
of vitamin D (1,25-dihydroxyvitamin D3). In addition, 
the primary outcome of these studies was not the effect 
of vitamin D supplementation on glucose metabolism. 
In the placebo-controlled Women’s Health Initiative 
(WHI), the use of calcium supplement of 1,000 mg 
per day and vitamin D3 400 IU per day failed to reduce 
the risk of progression to diabetes over a period of 
seven years (40). The null result may, however, be 
attributable to the use of a low dose of vitamin D in the 
active treatment group.
In a systematic review (41) of studies published 
in English using Medline up to the end of February 
2011, a total of eight observational studies and 11 
interventional studies were included, in order to 
ascertain the association between vitamin D status and 
the incidence of type 2 diabetes mellitus and the effect 
of vitamin D supplementation on blood glucose results. 
The daily ingestion of > 500 IU of 25(OH)D reduced 
the risk of diabetes by 13% a against an ingestion of 
< 200 IU per day. Individuals with higher 25(OH)D 
levels (> 25 ng/mL) had a lower risk of developing 
type 2 diabetes than those in the group with 25(OH)
D levels of < 14 ng/mL. In a post-hoc analysis of eight 
studies comprising individuals with normal glucose 
tolerance levels at baseline, and in three small studies 
(32-60) of patients with type 2 diabetes vitamin D 
supplementation had no effect on the blood glucose 
results.
To determine whether vitamin D supplementation, 
with or without calcium, improved glucose homeostasis 
in adults at risk for diabetes, a randomized, double-
blind, placebo-controlled study (42) was conducted, 
assigned in a 2-by-2 factorial-design, in which patients 
were given either cholecalciferol (2000 IU once 
daily), or calcium carbonate (400 mg twice daily) for 
16 weeks. The results showed that supplementation 
with cholecalciferol, but not with calcium, improved 
beta cell function and had only a marginal effect on 
attenuating the rise in glycated hemoglobin. However, 
supplementation with cholecalciferol does not improve 
glycemic control in diabetic subjects with normal serum 
25(OH)D levels.
vitamin D and cardiovascular disease
A growing body of evidence suggests that low levels 
of 25(OH)D may adversely affect the cardiovascular 
system (43). 
Cross-sectional studies show associations between 
decreased sun exposure or hypovitaminosis D and 
Vitamin D and diabetes mellitus
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increased risk for myocardial infarction, stroke, heart 
failure, and peripheral arterial disease, and studies in 
rodents have shown that vitamin D protects against 
cardiac hypertrophy and myocardial dysfunction (44). 
Several mechanisms may explain the link between 
vitamin D deficiency and cardiovascular disease. 
Vascular smooth muscle cells and endothelial cells 
express receptors for vitamin D and have the ability to 
convert circulating 25(OH)D into 1,25(OH)2 D (45). 
In vitro, activated 1,25(OH)2D suppresses renin gene 
expression, and regulates the growth and proliferation 
of vascular smooth muscle cells and cardiomycytes 
(44,46). 
Demographic data in a sample representative of 
the United States from the Third National Health and 
Nutrition Examination Survey revealed that 25(OH)
D levels are associated with important cardiovascular 
disease risk factors. The prevalence of diabetes mellitus 
(odds ratio 1.98), obesity (odds ratio 2.29), increased 
levels of triglycerides (odds ratio 1.47) and arterial 
hypertension (odds ratio 1.30) were all significantly 
greater in the lower quartiles of the 25(OH)D serum 
levels than in the higher quartiles (< 0.001 for all) 
(47). Pilz and cols. found an association of vitamin 
D deficiency with heart failure and sudden cardiac 
death (SCD) in a large cross-sectional study of patients 
referred for coronary angiography. After adjustment for 
cardiovascular risk factors, the hazard ratios (with 95% 
confidence intervals) for death due to heart failure and 
for SCD were 2.84 (1.20-6.74) and 5.05 (2.13-11.97), 
respectively, when comparing patients with severe 
vitamin D deficiency [25(OH)D < 10 ng/mL] with 
persons in the optimal range [25(OH)D > 30 ng/mL] 
(48). On the other hand, a systematic review and meta-
analysis found (51 eligible trials of moderate quality) 
that 25(OH)D was associated with nonsignificant 
effects on the patient-important outcomes of death 
[RR, 0.96; 95% confidence interval (CI), 0.93, 1.00; 
P = 0.08], myocardial infarction (RR, 1.02; 95% CI, 
0.93, 1.13; P = 0.64), and stroke (RR, 1.05;95%CI, 
0.88, 1.25; P = 0.59) (49).
A study verified the relationship between hypovita-
minosis D and intimal medial thickening (IMT) of the 
common carotid artery, measured by ultrasonography 
among 390 type 2 diabetic patients. Hypovitaminosis 
D was defined as a serum 25(OH)D concentration ≤ 
15 ng/mL and IMT as a focal thickening > 1.2 mm at 
the level of the common carotid artery. They found a 
strong inverse and independent the association between 
serum 25(OH)D and carotid artery IMT. The patients 
with hypovitaminosis D (n = 130) had a marked in-
crease in common carotid artery IMT (1.10 ± 0.15 vs. 
0.87 ± 0.14 mm, p < 0.001) (50).
Despite a large number of cross-sectional studies 
and a limited number of clinical trials that evaluated 
25(OH)D concentrations as a potential determinant of 
cardiovascular disease and type 2 diabetes, it remains 
uncertain whether improving vitamin D status would 
reduce risk of these conditions. 
vitamin D and type 1 diabetes mellitus 
Type 1 diabetes mellitus (T1D) is caused by a 
complex autoimmune process associated with altered 
humoral and cellular immunity. The autoimmune 
response involves both β-cell specific autoantibodies 
and autoreactive pathogenic CD4 and CD8T cells 
infiltrating the pancreatic islets (insulitis). The pre-
diabetic phase of T1D may have relapsing-remitting 
course that leads to slowly progressive pancreatic islet 
β-cell failure. Progression occurs depending on the 
interplay between antigen spreading, β-cell proliferation 
and loss of regulatory T (Treg) cells.
In the last few years, intervention trials in new-
onset T1D has been taken to silence and/or modulate 
this altered immune response. A growing body of 
evidence from animal and in vitro studies suggests 
the potential of 25(OH)D to modulate the immune 
response: 1) the presence of VDR on human activated 
inflammatory cells, 2) the ability of 25(OH)D to inhibit 
lymphocyte proliferation and 3) the ability of activated 
macrophages to produce 1,25(OH)2D, expressing 
CYP27B1. Additionally, most tissues in the body have 
VDR, which are also expressed in activated T and B 
human lymphocytes. 
Initial studies showed that 25(OH)D not only acts 
suppressing lymphocyte proliferation, but may also 
modify the Th1/Th2 cytokine profile, which might 
help to limit the potential tissue damage associated 
with Th1 cellular immune responses (51). However 
a subsequent analysis demonstrated that although in 
vitro 25(OH)D seems to support a shift from Th1 to 
Th2, its effects in vivo on T cells are more complex, 
showing both inhibition of Th1 and Th2 cytokines, 
and reduced levels of Th1 cells.
In animal models (mostly NOD mouse) high doses 
of 1,25(OH)2D successfully reduce the incidence 
of diabetes by decreasing the numbers of effector T 
Vitamin D and diabetes mellitus
Co
py
rig
ht
©
 A
BE
&
M
 to
do
s o
s d
ire
ito
s r
es
er
va
do
s.
6  Arq Bras Endocrinol Metab. 2014;58/1
cells, inducting Treg cells and reducing chemokine 
production by islet cells (52). Treg cells exert suppressor 
rather than effector functions, and it seems that the 
differentiation of Treg is an important mechanism 
linking 1,25(OH)2D and adaptive immunity. The 
immunosuppressive mechanism is probably mediated 
by the induction of tolerogenic antigen presenting cells 
(like dendritic cells), increased IL-10 secretion and the 
expression of Toll-like receptor 9 (TLR9) by Tregs, 
suggesting a novel link between innate and adaptive 
immune response.
It also has been reported that exposition of human 
β cell to 1,25(OH)2D protects them from death 
by reducing expression of MHC class I molecules, 
inducing expression of anti-apoptotic A20 protein and 
decreasing expression of FAS (that regulates activation-
induced cell death) (53).
In vivo studies have shown that 1,25(OH)2D 
inhibits the expression of inflammatory cytokines in 
monocytes, such as IL-6, TNF-alfa, IL-8, and IL-12 
in normal individuals. The influence of this vitamin on 
cytokine production by lymphocytes may be another 
important link between the 25(OH)D and the immune 
system (54). Other facets of T-cell function may also 
be affected by the hormone, such as the homing of 
T cells to specific tissues. The studies suggested that 
1,25(OH)2D acts inhibiting migration of T cells to 
lymph nodes.
There are data showing that 25(OH)D supplemen-
tation to offspring during infancy, as well as dietary 
exposure during pregnancy, was associated with a re-
duced risk of human type 1 diabetes. Children who 
took 2000UI regularly had a RR of 0.22 (0.05-0.89), 
while children suspected of having rickets during the 
first year of life had a RR of 3.0 (1.0-9.0) risk of T1D 
(10). It is interesting to observe that in Finland, while 
the recommended dosage of 25(OH)D has decreased 
gradually in the last few decades, associated with a de-
crease in compliance to supplementation recommenda-
tions, there was an increase in the incidence of T1D. 
Together with the observation that incidence rates of 
T1D tended to be higher at higher latitudes in both 
hemispheres, the association of ultraviolet B irradiance 
with risk of T1D was observed in 51 regions world-
wide, which raises the possibility of 25(OH)D having 
a role in the development of the disease. In addition, 
a number of observational studies have revealed an as-
sociation between 25(OH)D deficiency, and the prev-
alence of T1D in children and adolescents compared 
with non-diabetic individuals (55). 
Another piece of evidence of the complex role of 
25(OH)D is the extensive genetic analyses linking 
the polymorphic variation in the genes for several 
components of the 25(OH)D metabolic and signaling 
system to T1D. Some specific VDR gene haplotypes 
appear to protect against diabetes, while polymorphisms 
in the CYP27B1 gene have been shown to affect diabetes 
susceptibility (56,57). Given the evidence that variation 
in the CYP27B1 etiologically contributes to T1D risk, 
other genes that control vitamin D metabolism are also 
biologically plausible candidates, and should be studied. 
In a clinical setting, two recent trials found no 
significant effect of 1,25(OH)2D on the preservation 
of β-cell function after type 1 diabetes onset (58,59). 
Nevertheless, the dose and mechanistic action of 
vitamin D are still under discussion. On the other hand, 
in a randomized, double-blind, placebo-controlled 
trial in new-onset T1D, we studied the effect of 2000 
IU of 25(OH)D on peripheral cytokine levels, Treg 
cells and the decline of residual β-cell function. We 
found that the cumulative incidence of progression to 
undetectable (≤ 0.1 ng/ml) fasting serum C-peptide 
during the 18 months of follow-up reached 18.7% in 
the 25 (OH)D group, and 62.5% in the placebo group 
(P = .012) while stimulated C-Peptide reached this 
level in 6.2% of the 25(OH)D and 37.5% of placebo 
group (P = .047). We also found a tendency to increase 
IL-10 and Treg cells (CD4+CD25+Foxp3), which might 
have contributed to the less progressive β-cell decay in 
the 25(OH)D group (60). 
In any case, further studies based on large patient 
cohorts are needed to show whether the administration 
of 25(OH)D or 1,25(OH)2D significantly reduces 
the risk of T1D or contribute to the preservation of 
C-peptide after the diagnosis.
CONClUSIONS
There is evidence that vitamin D deficiency leads 
to glucose intolerance and predisposes to type 2 
diabetes mellitus, while the restoration of vitamin D 
levels may reduce the risk of type 1 diabetes mellitus. 
Despite observational studies showing a strong 
association between vitamin D deficiency and diabetes 
mellitus, randomized clinical trials with vitamin D 
supplementation are of short duration, with small 
numbers of patients, and small doses of vitamin D 
Vitamin D and diabetes mellitus
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supplementation, thereby not permitting any definitive 
conclusions. Questions persist about the optimal level 
of 25 (OH)D to prevent the risk of developing diabetes 
mellitus. However, a large long-term clinical trials are 
needed to clarify these issues. Vitamin D is inexpensive 
and should a trial confirm its benefit in the prevention 
of diabetes, it will have a major impact on public health.
Disclosure: no potential conflict of interest relevant to this article 
was reported.
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